Sage Therapeutics, Inc.

NasdaqGM:SAGE Stok Raporu

Piyasa değeri: US$300.4m

Sage Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Sage Therapeutics CEO'su Barry Greene, Dec2020 tarihinde atandı, in görev süresi 3.92 yıldır. in toplam yıllık tazminatı $ 6.24M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.8% maaş ve 87.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.14% ine doğrudan sahiptir ve bu hisseler $ 417.68K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 9.3 yıldır.

Anahtar bilgiler

Barry Greene

İcra Kurulu Başkanı

US$6.2m

Toplam tazminat

CEO maaş yüzdesi12.8%
CEO görev süresi3.9yrs
CEO sahipliği0.1%
Yönetim ortalama görev süresi1.3yrs
Yönetim Kurulu ortalama görev süresi9.3yrs

Son yönetim güncellemeleri

Recent updates

CNS Drug Development: Same As It Ever Was

Nov 19

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Oct 07

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Jul 25

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Well-Funded But Uninspiring Data

Mar 24

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Feb 26
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Biogen's Backing May See It Through

Jan 04

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05
What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

CEO Tazminat Analizi

Barry Greene'un ücretlendirmesi Sage Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$338m

Jun 30 2024n/an/a

-US$446m

Mar 31 2024n/an/a

-US$503m

Dec 31 2023US$6mUS$799k

-US$541m

Sep 30 2023n/an/a

-US$656m

Jun 30 2023n/an/a

-US$592m

Mar 31 2023n/an/a

-US$558m

Dec 31 2022US$6mUS$761k

-US$533m

Sep 30 2022n/an/a

-US$510m

Jun 30 2022n/an/a

-US$503m

Mar 31 2022n/an/a

-US$484m

Dec 31 2021US$59mUS$735k

-US$458m

Sep 30 2021n/an/a

US$642m

Jun 30 2021n/an/a

US$666m

Mar 31 2021n/an/a

US$637m

Dec 31 2020US$836kUS$53k

US$606m

Tazminat ve Piyasa: Barry 'nin toplam tazminatı ($USD 6.24M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.24M ).

Tazminat ve Kazançlar: Barry şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Barry Greene (61 yo)

3.9yrs

Görev süresi

US$6,237,491

Tazminat

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Barry Greene
President3.9yrsUS$6.24m0.14%
$ 417.7k
Christopher Benecchi
Chief Operating Officerno dataUS$2.28m0.0081%
$ 24.5k
Laura Gault
Chief Medical Officer2.1yrsUS$1.27m0.018%
$ 52.7k
Mike Quirk
Chief Scientific Officer1.3yrsVeri yokVeri yok
Ashley Kaplowitz
Director of Investor Relationsno dataVeri yokVeri yok
Gregory Shiferman
Senior VP & General Counselno dataVeri yokVeri yok
Pamela Herbster
VP & Head of Peopleless than a yearVeri yokVeri yok
Helen Colquhoun
Senior Vice President of Drug Safety & Pharmacovigilanceno dataVeri yokVeri yok
Vanessa Procter
Senior Vice President of Corporate Affairs3yrsVeri yokVeri yok
Aaron Koenig
Medical Director of Early Clinical Developmentno dataVeri yokVeri yok
Maren Killackey
Senior Analyst of Investor Relationno dataVeri yokVeri yok
Jeff Boyle
Investor Contactno dataVeri yokVeri yok

1.3yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: SAGE 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Barry Greene
President4.1yrsUS$6.24m0.14%
$ 417.7k
Michael Cola
Independent Director10.2yrsUS$440.05k0%
$ 0
James Frates
Independent Director10.5yrsUS$435.05k0.0046%
$ 14.0k
David Farb
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Geno Germano
Independent Chair of the Board8.3yrsUS$417.55k0%
$ 0
Michael Rogawski
Member of Scientific Advisory Boardno dataVeri yokVeri yok
James Audia
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Christine Marx
Member of Scientific Advisory Boardno dataVeri yokVeri yok
A. Morrow
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Stephen Moss
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Scott Runyon
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Donald Stein
Member of Scientific Advisory Boardno dataVeri yokVeri yok

9.3yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SAGE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).